Heartflow, Inc. HTFL
Regular-session close
After hours · Nov 19, 7:50 PM ET
- YTD
- +53.10%
- 1 year
- +63.90%
5D -10.29 (-18.75%)
- Market cap
- 3.92B
- Revenue (ttm)
- 238.66M
- Profit margin
- -33.11%
- EPS (ttm)
- 0.65
- Shares out
- 87.89M
- P/E ratio
- 68.66
- Forward P/E
- -168.31
- YTD return
- +53.10%
- 1-year return
- +63.90%
- Volume
- 1.28M
- Avg volume
- 1.86M
- Open
- 46.57
- Previous close
- 45.89
- Day's range
- 44.38 – 47.51
- 52-week range
- 20.13 – 60.66
- Analysts
- Strong Buy
- Price target
- 65.00 (+45.6%)
- Earnings date
- Mar 17, 2027
Key statistics
- 50-day average
- 51.84
- 200-day average
- 35.47
- Enterprise value
- 3.89B
- Price / sales
- 16.44
- Price / book
- 13.87
- Revenue growth
- 57.40%
- Free cash flow
- -32.03M
- Total cash
- 167.74M
- Total debt
- 25.93M
- Return on equity
- -29.43%
- Short % of float
- 9.33%
Fundamental scorecard
6 of 25 checks passed on HTFL’s reported financials
6of 25 checks passed
- Value 0 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 59.00
- Target (mean)
- 65.00
- Target (high)
- 70.00
- Strong buy2
- Buy6
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 17, 2027
Expected Mar 17, 2027. Consensus EPS estimate -0.08509.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 17, 2027 | Dec 30, 2026 | -0.09 | — | — | — |
| Nov 12, 2026 | Sep 30, 2026 | -0.1029 | -0.03 | +0.07 | +70.85% |
| Aug 13, 2026 | Jun 30, 2026 | -0.13369 | -0.07 | +0.06 | +47.64% |
| May 14, 2026 | Mar 31, 2026 | -0.18763 | -0.16 | +0.03 | +14.73% |
| Mar 18, 2026 | Dec 31, 2025 | -0.18763 | -0.12 | +0.07 | +36.04% |
| Nov 12, 2025 | Sep 30, 2025 | -0.20 | -0.27 | -0.07 | -35.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 20, 2026 | Piper Sandler | reit | Overweight | Overweight |
| Sep 22, 2026 | Canaccord Genuity | main | Buy | Buy |
| Sep 9, 2026 | UBS | init | — | Neutral |
| Aug 14, 2026 | Canaccord Genuity | main | Buy | Buy |
| Aug 14, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Aug 14, 2026 | Piper Sandler | reit | Overweight | Overweight |
About Heartflow, Inc.
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries. The company provides Heartflow RoadMap Analysis that offers an intuitive anatomic visualization of the coronary arteries; Heartflow FFRCT Analysis, which calculates blood flow and pinpoints clinically; and Heartflow Plaque Analysis that provides a comprehensive assessment of coronary plaque, enabling optimized medical treatment strategies. Its platform provides insights on blood flow, stenosis, and plaque volume and composition by overcoming the limitations of traditional non-invasive imaging tests. HeartFlow, Inc. was formerly known as Cardiovascular Simulation, Inc. and changed its name to HeartFlow, Inc. in May 2009. The company was incorporated in 2007 and is headquartered in San Francisco, California.
- Sector
- Healthcare
- Industry
- Health Information Services
- Country
- United States
- Website
- heartflow.com
News
HeartFlow: A Post Q3 Assessment
HeartFlow: 3 Key Takeaways for Long-Term Investors Wells Fargo Maintains Overweight on HeartFlow, Raises Price Target to $70
Canaccord Genuity Maintains Buy on HeartFlow, Raises Price Target to $69
Stifel Maintains Buy on HeartFlow, Raises Price Target to $70
Baird Maintains Outperform on HeartFlow, Raises Price Target to $68
HeartFlow, Inc. (HTFL) Q3 2026 Earnings Call Transcript
What Heartflow (HTFL) Said on Its Q3 Earnings Call
HeartFlow (HTFL) Reports Q3 Loss, Beats Revenue Estimates HeartFlow Q3 Adj. EPS $(0.03) Beats $(0.10) Estimate, Sales $72.857M Beat $65.264M Estimate
Your note
Sign in to keep a note on HTFL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAIN CAPITAL LIFE SCIENCES INVESTORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Apr 29, 2026 | 0 |
| BARABE TIMOTHY CRAIG | Director | Conversion of Exercise of derivative security | Jul 21, 2026 | 188,231 |
| FARQUHAR JOHN C. M. | Chief Executive Officer | Conversion of Exercise of derivative security | Nov 9, 2026 | 251,983 |
| HEALTHCOR PARTNERS MANAGEMENT L.P. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Aug 10, 2025 | 0 |
| JONES MARIE L | Officer | Stock Award(Grant) | Sep 7, 2026 | 32,403 |
| LIGHTCAP JEFFREY C | Director | Conversion of Exercise of derivative security | Jul 23, 2026 | 6,991,240 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 6.87% | 6,040,943 | 269.61M | Sep 29, 2026 |
| Wellington Management Group, LLP | 6.31% | 5,548,202 | 247.62M | Sep 29, 2026 |
| FMR, LLC | 6.25% | 5,491,275 | 245.08M | Sep 29, 2026 |
| Bain Capital Life Sciences Investors, LLC | 5.06% | 4,448,158 | 198.52M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 4.23% | 3,719,472 | 166.00M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 3.77% | 3,315,690 | 147.98M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 6.59% | 5,795,579 | 258.66M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.81% | 2,467,177 | 110.11M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.26% | 1,987,442 | 88.70M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.03% | 1,781,440 | 79.51M | Jun 29, 2026 |
| BARON INVESTMENT Fd.S TRT -BARON DISCOVERY Fd. | 1.83% | 1,604,894 | 71.63M | Jun 29, 2026 |
| AIM Counselor Series TRT -Invesco Discovery Fd. | 1.45% | 1,275,225 | 56.91M | Aug 30, 2026 |
